ACC Previews Next Round Of Stent Wars: Ease-Of-Use Claims Will Be Key
This article was originally published in The Gray Sheet
Executive Summary
The singular U.S. market dominance of the cobalt-chromium everolimus-eluting stent known as Xience V or Promus is likely to be threatened next year as two new next-generation products make their way to market.